Patent intelligence · US
US 12171759
Methods and uses for treating anhedonia
Methods and uses for treating anhedonia
Patent details — US 12171759
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 24, 2024
- Expiration
- Dec 19, 2044
- Applicant
- Xenon Pharmaceuticals Inc.
- Claims
- 27
- CPC classes
- A61K, A61K31/472, A61P, A61P25/24
Quick answer
US 12171759 (Methods and uses for treating anhedonia) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Xenon Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/472, A61P, A61P25/24
More from Xenon Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12319657
Solid state crystalline forms of a selective potassium channel modulator
granted -
US 12178811
Methods of treating depressive disorders
granted -
US 11957675
Methods and uses for treating anhedonia
granted -
US 11325902
Benzenesulfonamide compounds and their use as therapeutic agents
granted -
US 11299490
Benzenesulfonamide compounds and their use as therapeutic agents
granted -
US 11203572
Substituted benzamides and methods of use thereof
granted -
US 11174268
Benzenesulfonamide compouds and their use as therapeutic agents
granted
Frequently asked questions
What is US patent 12171759?
US 12171759 (Methods and uses for treating anhedonia) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Dec 24, 2024. Expires Dec 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12171759?
Xenon Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 106 pharmaceutical patents for this assignee.
When does US 12171759 expire?
Our index shows an expiration date of Dec 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.